Dec 4
2024
Phanes Therapeutics’ PT217 granted Fast Track Designation by the FDA for NEPC
This is the second Fast Track Designation granted to PT217 by the agency SAN DIEGO, Dec. 4, 2024 /PRNewswire/ -- Phanes Therapeutics,...
Read More
Nov 6
2024
Phanes Therapeutics Announces the Appointment of Gastrointestinal Oncologist Prof. Zev Wainberg to its Clinical Advisory Board
SAN DIEGO, Nov. 5, 2024 /PRNewswire/ -- Phanes Therapeutics, Inc. (Phanes), a clinical stage biotech company focused on innovative drug discovery and...
Read More
Oct 8
2024
Phanes Therapeutics Announces First Patient Dosed in Clinical Study of PT886 in Combination with KEYTRUDA® (pembrolizumab)
SAN DIEGO, Oct. 8, 2024 /PRNewswire/ -- Phanes Therapeutics, Inc. (Phanes), a clinical stage biotech company focused on innovative drug discovery and...
Read More
Sep 9
2024
Phanes Therapeutics Announces First Patient Dosed in Clinical Study of PT886 in Combination with Chemotherapy
SAN DIEGO, Sept. 9, 2024 /PRNewswire/ -- Phanes Therapeutics, Inc. (Phanes), a clinical stage biotech company focused on innovative drug discovery and...
Read More
Aug 16
2024
Phanes Therapeutics’ PT217 receives Orphan Drug Designation for Neuroendocrine Carcinoma from the FDA
SAN DIEGO, Aug. 16, 2024 /PRNewswire/ -- Phanes Therapeutics, Inc. (Phanes), a clinical stage biotech company focused on innovative drug discovery and...
Read More
May 8
2024
Phanes Therapeutics, Inc. Announces Clinical Supply Agreement with Roche to Evaluate PT217 in Combination with an anti-PD-L1 Therapy
PT217 is Phanes' first-in-class bispecific antibody targeting DLL3 and CD47; atezolizumab (TECENTRIQ®) is Roche's anti-PD-L1 monoclonal antibody The clinical supply agreement will focus on...
Read More
Apr 9
2024
Phanes Therapeutics’ PT217 granted Fast Track Designation by the FDA
SAN DIEGO, April 8, 2024 /PRNewswire/ -- Phanes Therapeutics, Inc. (Phanes), a clinical stage biotech company focused on innovative drug discovery and development...
Read More
Mar 21
2024
Phanes Therapeutics’ PT886 granted Fast Track designation for the treatment of patients with metastatic claudin 18.2-positive pancreatic adenocarcinoma by the FDA
SAN DIEGO, March 20, 2024 /PRNewswire/ -- Phanes Therapeutics, Inc. (Phanes), a clinical stage biotech company focused on innovative drug discovery and...
Read More
Jan 30
2024
Phanes Therapeutics, Inc. announces granting of registered trademarks for its three proprietary technology platforms by the U.S. Patent and Trademark Office
SAN DIEGO, Jan. 29, 2024 /PRNewswire/ -- Phanes Therapeutics, Inc. (Phanes), a clinical stage biotech company focused on innovative drug discovery and...
Read More
Oct 16
2023
Phanes Therapeutics, Inc. Announces Clinical Trial Collaboration and Supply Agreement with Merck to Evaluate PT886 in Combination with KEYTRUDA® (pembrolizumab)
PT886 is Phanes' first-in-class bispecific antibody targeting claudin 18.2 and CD47; KEYTRUDA® (pembrolizumab) is Merck's anti-PD-1 The clinical trial collaboration will...
Read More
